Nanoscope Therapeutics begins FDA submission for gene-agnostic therapy to treat retinitis pigmentosa
Nanoscope Therapeutics has initiated a rolling submission for its Biologics [...]
Pharvaris has adjusted its guidance for topline results from its [...]
VIVES Partners, managing company of VIVES Funds, has joined a [...]
New analysis reveals billions risked on overly complex trials that [...]
RNA therapeutics biotech Ochre Bio has appointed its founder and [...]
New alliance targets early 2026 for first-in-human trial of non-opioid [...]
Poland-based CDMO Mabion has completed the first GMP-compliant batch of [...]
CluePoints releases full speaker lineup for free virtual event focused [...]
PhaseV has secured $50 million in Series A funding to [...]